Publicacións en colaboración con investigadores/as de Hospital Universitario 12 de Octubre (12)

2024

  1. First-line therapy with palbociclib in patients with advanced HR+/HER2− breast cancer: The real-life study PALBOSPAIN

    Breast Cancer Research and Treatment

  2. Indicators to evaluate quality of care in head and neck cancer in Spain

    Clinical and Translational Oncology, Vol. 26, Núm. 5, pp. 1089-1097

2023

  1. Association of Circulating Tumor Cells and Tumor Molecular Profile With Clinical Outcomes in Patients With Previously Untreated Metastatic Colorectal Cancer: A Pooled Analysis of the Phase III VISNÚ-1 and Phase II VISNÚ-2 Randomized Trials

    Clinical Colorectal Cancer, Vol. 22, Núm. 2, pp. 222-230

2021

  1. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

    Annals of Oncology, Vol. 32, Núm. 10, pp. 1245-1255

  2. Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer

    npj Precision Oncology, Vol. 5, Núm. 1

2020

  1. Detection and dynamics of circulating tumor cells in patients with high-risk prostate cancer treated with radiotherapy and hormones: A prospective phase II study

    Radiation Oncology, Vol. 15, Núm. 1

2017

  1. Weekly cabazitaxel plus prednisone is effective and less toxic for ‘unfit’ metastatic castration-resistant prostate cancer: Phase II Spanish Oncology Genitourinary Group (SOGUG) trial

    European Journal of Cancer, Vol. 87, pp. 30-37

2016

  1. SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan

    Supportive Care in Cancer, Vol. 24, Núm. 1, pp. 499-507

2014

  1. In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancer

    Cancer Research, Vol. 74, Núm. 22, pp. 6565-6577

2013

  1. Molecular diagnosis of endometrial cancer from uterine aspirates

    International Journal of Cancer, Vol. 133, Núm. 10, pp. 2383-2391

2009

  1. Akt activation synergizes with Trp53 loss in oral epithelium to produce a novel mouse model for head and neck squamous cell carcinoma

    Cancer Research, Vol. 69, Núm. 3, pp. 1099-1108

  2. Transgenic mice expressing constitutively active akt in oral epithelium validate KLFA as a potential biomarker of head and neck squamous cell carcinoma

    In Vivo, Vol. 23, Núm. 5, pp. 653-660